A user's experience with the Big 3 (minoxidil, finasteride and RU58841) hair loss treatment along with dermarolling. The dermaroller pin was 1.5mm used once per week and drew some blood but not a lot.
The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
The conversation is about experiences with GHK-Cu Copper and AHK-Cu Copper for hair regrowth and thickening. One user expressed skepticism about its effectiveness.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
The user is considering getting blood work to investigate the cause of ongoing hair loss despite using finasteride and dutasteride. Others suggest that while blood tests can provide useful health information, they may not change the hair treatment outcome.
The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.
The conversation discusses using a liposomal gel with Adenosine and caffeine for hair loss, questioning if caffeine's role as an adenosine receptor antagonist might counteract the benefits of Adenosine or worsen hair loss.
A user on Finasteride for over a year is asking if taking Glycine 1000 mg at night along with morning collagen peptides will increase DHT and cause hair loss. They are concerned about the potential impact on their hair loss treatment.
Male pattern baldness and diffuse thinning can both be forms of androgenetic alopecia (AGA), and it's important to consult a doctor for proper diagnosis. Treatments like Minoxidil, Finasteride, and biotin are discussed, but their effectiveness varies, and side effects are a concern.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.
The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.
The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.
The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.
OP had a doctor appointment, was advised to try B vitamins and change shampoo for hair loss, and may consider Finasteride if no improvement. Users suggest seeing a dermatologist directly, as vitamins likely won't help much with AGA.
The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.
Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.